Pharmacist‐led dosing reduces tacrolimus intrapatient variability in lung transplant recipients

Intrapatient variability (IPV) of tacrolimus has become a marker for predicting transplant outcomes, though minimal data exists regarding strategies to improve tacrolimus IPV. Following the implementation of comprehensive outpatient clinical pharmacy services, the impact of a dedicated lung transplant pharmacist on 1‐year tacrolimus variability and clinical outcomes in lung transplant recipients (LTRs) were investigated. A retrospective study of two LTR cohorts was conducted at a single‐center institution. Cohort 1 included LTRs from January 1, 2015 to December 31, 2017 with tacrolimus dose adjustments made by physicians or nurse practitioners, and were seen by a pharmacist on an ad hoc basis. Cohort 2 included LTRs from January 1, 2018 to December 31, 2019 with tacrolimus adjustments made solely by a pharmacist who saw them at each routine visit with the multidisciplinary team for the first year post‐transplant. The primary outcome assessed tacrolimus variability by the coefficient of variation 12 months post‐transplant. Secondary outcomes assessed post‐transplant hospital readmissions, acute cellular rejection (ACR), donor‐specific antibodies (DSA), and mortality at 12 months post‐transplant. No protocol changes occurred during the study period. Chi‐squared and t‐tests analyses were utilized. Sixty‐three LTRs were included, 39 patients in Cohort 1 and 24 in Cohort 2 with no significant differences between cohorts. At 1‐year post‐transplant, Cohort 2 had lower median tacrolimus variability (35.7% vs. 30.3%, p = 0.02) and more patients had a tacrolimus variability